New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

AIM ImmunoTech Inc. (AIM) vs Cardio Diagnostics Holdings, Inc. (CDIO)

AIM ImmunoTech Inc. and Cardio Diagnostics Holdings, Inc. are both Biotechnology companies. AIM ImmunoTech Inc. and Cardio Diagnostics Holdings, Inc. are of similar size ($4.9M and $4.8M). Cardio Diagnostics Holdings, Inc. grew revenue faster over the last twelve months: −3.16% against −18.8%. AIM ImmunoTech Inc. has the higher net margin (−15,526.4% vs −42,401.3%) and the lower return on invested capital (−5,687.5% vs −228.0%). Across the 16 metrics below, AIM ImmunoTech Inc. leads on 8 and Cardio Diagnostics Holdings, Inc. on 8.

Valuation

Metric AIM CDIO Biotechnology median
P/E n/m n/m 8.26
P/S 42.85 319.11 9.20
P/B 0.55 0.85 2.09
Price to free cash flow n/m n/m 24.49
EV/EBITDA 0.26 n/m 0.67
EV/Sales (28.62) 61.40 9.05
Earnings yield (2,206.08%) (153.33%) (34.24%)
Free cash flow yield (322.03%) (118.47%) (24.77%)

Profitability

Metric AIM CDIO Biotechnology median
Gross margin 38.46% 100.00% 70.18%
Operating margin (12,800.00%) (42,328.76%) 0.00%
Net margin (15,526.37%) (42,401.31%) 0.00%
Free cash flow margin (13,792.31%) (37,804.58%) 0.00%
Return on equity (2,828.63%) (93.55%) (51.58%)
Return on assets (185.36%) (87.24%) (45.91%)
Return on invested capital (5,687.50%) (227.99%) 0.00%

Growth

Metric AIM CDIO Biotechnology median
Revenue growth (TTM) (18.75%) (3.16%) 7.20%
EPS growth (last fiscal year) 72.19% 60.15% 29.04%
Revenue growth, 5-year CAGR (11.60%) — 9.48%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric AIM CDIO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.75 17.44 4.83
Net debt to EBITDA 0.22 0.84 1.01

Dividend

Metric AIM CDIO Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric AIM CDIO Biotechnology median
Market cap 4.79m 4.88m 155.23m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack